Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines

Journal of Medicinal Chemistry

Volumn 43, Issue 26, 2000, Pages 4948-4963

  Natchus, M G ^a   Bookland, R G ^a   De, B ^a   Almstead, N G ^a   Pikul, S ^a   Janusz, M J ^a   Heitmeyer, S A ^a   Hookfin, E B ^a   Hsieh, L C ^a   Dowty, M E ^a   Dietsch, C R ^a   Patel, V S ^a   Garver, S M ^a   Gu, F ^a   Pokross, M E ^a   Mieling, G E ^a   Baker, T R ^a   Foltz, D J ^a   Peng, S X ^a   Bornes, D M ^a   Strojnowski, M J ^a   Taiwo, Y O ^a   more..

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CGS 27023A; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; TANOMASTAT;

ANIMAL MODEL; ARTICLE; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; NONHUMAN; OSTEOARTHRITIS; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; CARTILAGE, ARTICULAR; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROXAMIC ACIDS; IODOACETATES; MALE; MATRIX METALLOPROTEINASE 3; METALLOENDOPEPTIDASES; MODELS, MOLECULAR; OSTEOARTHRITIS, KNEE; PROLINE; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034727847     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000246e     Document Type: Article

References (32)

1. Design therapeutic application of matrix metalloproteinase inhibitors
2. Clinical trials of a stromelysin inhibitor: Osteoarthritis, matrix metalloproteinase inhibition, cartillage loss, surrogate markers, and clinical implications
3. Matrix metalloproteinase inhibitors in the treatment of arthritis
4. Osteoarthritic lesions: Involvement of three different collagenases
5. Expression of matrix metalloproteinase 9 (96-Kd gelatinase B) in human rheumatoid arthritis
6. Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis
7. Recent advances in inhibitors of matrix metalloproteinases for cancer therapy
8. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system
9. Matrix metalloproteinases and diseases of the CNS
10. Delayed-type hypersensivity lesions in the central nervous system are prevented by inhibitors of matrix-metalloproteinases
11. Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function
12. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure
13. Dynamic role of extracellular matrix metalloproteinases in heart failure
14. Inhibitors: Experimental and clinical studies
15. Marimastat (British Biotech plc.)
16. Design and synthesis of conformationally-constrained MMP inhibitors
17. Design, synthesis and biological evaluation of potent thiazine and thiazapine based MMP inhibitors
18. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors
19. Design, synthesis and biological evaluation of MMP inhibitors derived from a modified proline scaffold
20. Discovery of potent, achiral matrix metalloproteinase inhibitors
21. A novel coumarin-labeled peptide for sensitive continuous assays of the matrix metalloproteinases
22. A metalloproteinase from human rheumatiod synovial fibroblasts that digests connective tissue matrix components. Purification and characterization
23. Insights into MMP-TIMP interactions
24. Improved prediction of in-vivo peroral absorption form in-vitro intestinal permeability using an internal standard to control for intra- and inter-rat variability
25. The unusual effect of pyridyl group on the transcellular transport of compounds across the Caco-2 cell monolayers
26. Monoiodoacetate-induced experimental osteoarthritis. A dose-response study of loss of mobility, morphology and biochemistry
27. Tierexperimentelle gonarthrose der ratte und ihre therapie mit glykosaminoglykanpolysulfat (GAGPS)
28. Exercise increases osteophyte formation and diminishes fibrilliations following chemically induced articular cartillage injury
29. A highly efficient and general N-monomethylation of functionalized primary amines via formylation and borane-methyl sulfide reduction
30. Crystal structure of the stromelysin catalytic domain at 2 Å resolution: Inhibitor-induced conformational changes